Fair value adjustment to acquisition-date inventory.

No definition available.

Name:	asrt_BusinessAcquisitionStepUpInValueOfInventories
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of decrease in the rebate payment.

+ References

No definition available.

+ Details

Name:	asrt_DecreaseInRebatePayment
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of increase in the purchase consideration and fair value of product rights.

+ References

No definition available.

+ Details

Name:	asrt_IncreaseInPurchaseConsiderationAndFairValueOfProductRights
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of the license fee incurred during the period.

+ References

No definition available.

+ Details

Name:	asrt_LicenseFee
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The period of time for giving written notice of termination as per the agreement.

+ References

No definition available.

+ Details

Name:	asrt_PeriodForGivingWrittenNoticeOfTermination
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount represents the amount of rebate estimated on the date of acquisition.

+ References

No definition available.

+ Details

Name:	asrt_RebatesEstimated
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The period of time the Company is responsible for marketing and selling under the License Agreement.

+ References

No definition available.

+ Details

Name:	asrt_TermForSellingAndMarketing
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of time the counterparty to the license agreement is responsible for selling, after the Company's term is completed.

+ References

No definition available.

+ Details

Name:	asrt_TermForSellingCounterparty
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of time the license agreement last following the first commercial sale in the U.S.

+ References

No definition available.

+ Details

Name:	asrt_TermOfLicenseAgreement
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.

+ References

No definition available.

+ Details

Name:	us-gaap_AssetsFairValueAdjustment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) on sale or disposal of intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7,9)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainLossOnDispositionOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.

+ References

No definition available.

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=asrt_EndoPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=asrt_SlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=asrt_ArchimedeLazandaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=asrt_CebranopadolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=asrt_GainOnSettlementAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=asrt_JanssenNucyntaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS - Narrative (Details)					1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
ACQUISITIONS - Narrative (Details)	Nov. 07, 2017 USD ($)	Nov. 17, 2015 USD ($) patent	Apr. 02, 2015 USD ($)	Jan. 15, 2015 USD ($)	Jan. 31, 2018	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2015 USD ($)
Business Acquisition [Line Items]
Research and development expenses						$ 2,127,000	$ 1,761,000		$ 5,835,000	$ 12,459,000
Senior Notes
Business Acquisition [Line Items]
Aggregate principal amount of notes issued			$ 575,000,000.0			$ 307,500,000			$ 307,500,000
Proceeds from Issuance of Debt			562,000,000
Endo
Business Acquisition [Line Items]
Number of patents infringed (patent) \| patent		3
Slan \| License Agreement
Business Acquisition [Line Items]
License agreement term	10 years
Company's marketing and selling term	7 years
Slan's selling term after the Company's	3 years
Research and development expenses	$ 24,900,000
License fee	$ 5,000,000
Lazanda
Business Acquisition [Line Items]
Gain on divestiture											$ 17,100,000
Cebranopadol
Business Acquisition [Line Items]
Research and development expenses		$ 54,900,000
Cash Paid		25,000,000
Contingent consideration payable		0
Period of time written notice of termination					120 days
Cebranopadol \| Endo
Business Acquisition [Line Items]
Non-cash adjustment		29,900,000
Cebranopadol \| Endo \| Non-cash gain on settlement agreement
Business Acquisition [Line Items]
Non-cash adjustment		$ 29,900,000
NUCYNTA
Business Acquisition [Line Items]
Cash Paid			1,050,000,000	$ 1,050,000,000
Amount of decrease in the rebate payment								$ 500,000
Amount of rebate payable estimated on the acquisition date			10,500,000
Increase in the purchase consideration and fair value of NUCYNTA U.S product rights								$ 500,000
Business acquisition step up in value of inventories			$ 5,900,000
Estimated useful life of intangible asset			10 years
NUCYNTA \| Senior Notes
Business Acquisition [Line Items]
Proceeds from Issuance of Debt			$ 550,000,000
NUCYNTA \| Selling, general and administrative expense
Business Acquisition [Line Items]
Non-recurring transaction costs												$ 12,300,000